To systematically evaluate the clinical efficacy and safety of fosaprepitant combined with 5-hydroxytryptamine 3 receptor antagonists (5-HT3RA) (with or without dexamethasone) on the chemotherapy-induced vomiting in pediatric cancer patients. This evidence concerns the gene HTR3A and cancer.